Vectura’s portfolio has emerged from the Company’s product development, formulation and drug delivery expertise and is currently centred around developing inhaled products to address unmet needs in airways diseases.

We continue to focus on balancing the unmet needs of all stakeholders (patients, physicians, payors) with commercial attractiveness and exploiting valuable niches in our therapeutic space.

   Investors

Date: 30/07/2015

Share price summary

1

WE INNOVATE

2

WE DEVELOP

3

WE COLLABORATE

Annual report

AR-15.png

Download annual report

Presentations and webcasts

25 June 2015

J.P. Morgan European Healthcare Conference, London

24 June 2015

ROTH 2nd Annual Healthcare Day, London

2 Jun 2015

Jefferies 2015 Healthcare Conference, New York - Vectura presenting 02:30 EDT/19:30 BST

View full list